Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 56 min ago
Peer-reviewedCC BY 4.0JMIR Medical Informatics

Differential Diagnosis of Early-Stage Pulmonary Sarcoidosis With Normal Serum Angiotensin-Converting Enzyme Activity Using Peripheral Blood Indicators: Machine Learning Models Development and Validation

4 affiliations
  1. 1Shanghai Key Laboratory of Tuberculosis Shanghai Pulmonary Hospital, Tongji University School of Medicine Shanghai China
  2. 2School of Public Health, the Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University Guiyang China
  3. 3Puxing Community Health Center, Pudong New District Shanghai China
  4. 4Department of Respiratory Medicine Shanghai Pulmonary Hospital, Tongji University School of Medicine Shanghai China

Abstract

Background: Early-stage pulmonary sarcoidosis with serum angiotensin-converting enzyme (sACE) activity within the normal range is difficult to distinguish from other pulmonary diseases with similar radiographic characteristics.

Objective: This study aimed to develop and validate machine learning (ML)–based diagnostic models for differentiating early-stage pulmonary sarcoidosis using indices from routine peripheral blood tests.

Methods: From May 2014 to May 2021, a total of 1142 patients with atypical initial pulmonary imaging findings were enrolled. After applying strict inclusion and exclusion criteria, 420 cases were divided into sarcoidosis and nonsarcoidosis groups (including mediastinal lymph node tuberculosis [MLNT], lung cancer, lymphoma, and pneumoconiosis), then stratified by sex and randomly split (7:3) into training and validation sets. Features were selected via univariate analysis (P<.10), the Boruta algorithm, and least absolute shrinkage and selection operator regression. Six ML algorithms—logistic regression (LR), random forest, support vector machine (SVM), extreme gradient boosting, k‑nearest neighbor, and naïve Bayes—were compared using area under the curve (AUC), accuracy, sensitivity, specificity, F1-score, Brier score, calibration assessment, and decision curve analysis. Shapley Additive Explanations was used for interpretability. The selected models were deployed as an interactive Shiny web application.

Results: After stratification, the male group comprised 224 cases (sarcoidosis n=42; MLNT: n=39; lung cancer: n=106; lymphoma: n=9; pneumoconiosis: n=28), and the female group comprised 196 cases (sarcoidosis: n=100; MLNT: n=39; lung cancer: n=49; lymphoma: n=4; pneumoconiosis: n=4). Models were selected based on comprehensive evaluation of multiple performance metrics, including AUC, accuracy, specificity, F1-score, and Brier score. The selected model for the male group was SVM, incorporating the following indices: age, lymphocyte count (Lym#), red cell distribution width standard deviation, D-dimer, sACE, cluster of differentiation 4-positive T cells to cluster of differentiation 8-positive T cells ratio (CD4+/CD8+), erythrocyte sedimentation rate, triglyceride to high-density lipoprotein cholesterol ratio (TG/HDLC), basophil count, and total protein. The selected model for the female group was LR, using Lym#, sACE, total cholesterol, TG/HDLC, glucose, CD3+%, and CD8+%. The validation set results showed AUCs of 0.896 (95% CI 0.746-1.000) and 0.762 (95% CI 0.632-0.892), sensitivities of 0.700 (95% CI 0.397-0.892) and 0.679 (95% CI 0.493-0.821), and specificities of 0.942 (95% CI 0.844-0.980) and 0.815 (95% CI 0.633-0.918), respectively.

Conclusions: Based on sex‑stratified strategies, the models demonstrated preliminary discriminative ability for differentiating early‑stage pulmonary sarcoidosis with normal sACE from other pulmonary diseases. However, the wide CIs preclude definitive conclusions about clinical performance, and external validation in larger cohorts is needed.

Related

  1. Angiotensin-Converting Enzyme in Patients With Early-Stage Psychosis
    Kun Yang, Luisa Longo, Pasquale Di Carlo +11
    JAMA PsychiatryPeer-reviewedLicence not statedFull text2 citedPsychiatry & mental healthPMC
  2. Case-control study on the association of angiotensin-converting enzyme gene I/D rs4646944 single nucleotide polymorphism and young-onset cryptogenic ischemic stroke in an Algerian cohort Estudo de caso-controle sobre associação do polimorfismo de nucleotídeo único I/D rs4646944 do gene da enzima conversora de angiotensina e acidente vascular isquêmico criptogênico de início precoce em coorte argelina
    Mohamed Lebsir, Mohamed Larbi Rezgoun, Boubekeur Saddik Fekraoui +4
    Jornal vascular brasileiroPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Vascular Remodelling in Idiopathic Nephrotic Syndrome with Administration of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
    H. Dimiati, S. Haris, K. Hasballah +1
    medRxivPreprintCC BYFull textGeneral medicinemedRxiv
  4. Glioblastoma model mouse rescue from mortality by brain-targeted catalytically-enhanced angiotensin-converting enzyme 2 mutant-antibody fusion protein
    P. Heinzelman, G. R. Nageeb, J. Choi +4
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxiv
  5. Obesity and Diabetes Increase SARS-CoV-2 Susceptibility Through Angiotensin-Converting Enzyme 2, Immunologic, and Gut Microbial Dysregulation
    Mahmoud Gheblawi, Mobin Khoramjoo, Mohamed Elaish +29
    JACC: Basic to Translational SciencePeer-reviewedCC BY-NC-ND 4.0Full textInfectious diseasePMC
BibTeX
@article{wang2026differential,
  title = {{Differential Diagnosis of Early-Stage Pulmonary Sarcoidosis With Normal Serum Angiotensin-Converting Enzyme Activity Using Peripheral Blood Indicators: Machine Learning Models Development and Validation}},
  author = {Lixiuyun Wang and Yafei Tang and Jun Ma and Shuqi Wang and Guoqiang Yang and Jin Huang and Qiuhong Li and Yonghong Feng},
  journal = {JMIR Medical Informatics},
  year = {2026},
  month = oct,
  doi = {10.2196/86639},
  url = {https://doi.org/10.2196/86639},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Differential Diagnosis of Early-Stage Pulmonary Sarcoidosis With Normal Serum Angiotensin-Converting Enzyme Activity Using Peripheral Blood Indicators: Machine Learning Models Development and Validation
AU  - Lixiuyun Wang
AU  - Yafei Tang
AU  - Jun Ma
AU  - Shuqi Wang
AU  - Guoqiang Yang
AU  - Jin Huang
AU  - Qiuhong Li
AU  - Yonghong Feng
PY  - 2026
DA  - 2026/10/26
JO  - JMIR Medical Informatics
DO  - 10.2196/86639
UR  - https://doi.org/10.2196/86639
AB  - Background: Early-stage pulmonary sarcoidosis with serum angiotensin-converting enzyme (sACE) activity within the normal range is difficult to distinguish from other pulmonary diseases with similar radiographic characteristics.  Objective: This study aimed to develop and validate machine learning (ML)–based diagnostic models for differentiating early-stage pulmonary sarcoidosis using indices from routine peripheral blood tests.  Methods: From May 2014 to May 2021, a total of 1142 patients with atypical initial pulmonary imaging findings were enrolled. After applying strict inclusion and exclusion criteria, 420 cases were divided into sarcoidosis and nonsarcoidosis groups (including mediastinal lymph node tuberculosis [MLNT], lung cancer, lymphoma, and pneumoconiosis), then stratified by sex and randomly split (7:3) into training and validation sets. Features were selected via univariate analysis (P<.10), the Boruta algorithm, and least absolute shrinkage and selection operator regression. Six ML algorithms—logistic regression (LR), random forest, support vector machine (SVM), extreme gradient boosting, k‑nearest neighbor, and naïve Bayes—were compared using area under the curve (AUC), accuracy, sensitivity, specificity, F1-score, Brier score, calibration assessment, and decision curve analysis. Shapley Additive Explanations was used for interpretability. The selected models were deployed as an interactive Shiny web application.  Results: After stratification, the male group comprised 224 cases (sarcoidosis n=42; MLNT: n=39; lung cancer: n=106; lymphoma: n=9; pneumoconiosis: n=28), and the female group comprised 196 cases (sarcoidosis: n=100; MLNT: n=39; lung cancer: n=49; lymphoma: n=4; pneumoconiosis: n=4). Models were selected based on comprehensive evaluation of multiple performance metrics, including AUC, accuracy, specificity, F1-score, and Brier score. The selected model for the male group was SVM, incorporating the following indices: age, lymphocyte count (Lym#), red cell distribution width standard deviation, D-dimer, sACE, cluster of differentiation 4-positive T cells to cluster of differentiation 8-positive T cells ratio (CD4+/CD8+), erythrocyte sedimentation rate, triglyceride to high-density lipoprotein cholesterol ratio (TG/HDLC), basophil count, and total protein. The selected model for the female group was LR, using Lym#, sACE, total cholesterol, TG/HDLC, glucose, CD3+%, and CD8+%. The validation set results showed AUCs of 0.896 (95% CI 0.746-1.000) and 0.762 (95% CI 0.632-0.892), sensitivities of 0.700 (95% CI 0.397-0.892) and 0.679 (95% CI 0.493-0.821), and specificities of 0.942 (95% CI 0.844-0.980) and 0.815 (95% CI 0.633-0.918), respectively.  Conclusions: Based on sex‑stratified strategies, the models demonstrated preliminary discriminative ability for differentiating early‑stage pulmonary sarcoidosis with normal sACE from other pulmonary diseases. However, the wide CIs preclude definitive conclusions about clinical performance, and external validation in larger cohorts is needed.
SN  - 2291-9694
ER  -